This segment focuses on the research, development, and clinical evaluation of novel cancer therapies. eFFECTOR Therapeutics utilizes its proprietary STRI platform to discover and develop small molecule inhibitors targeting key translation regulators. Research and development activities include preclinical studies, clinical trials, and biomarker identification. The lead product candidates, Tomivosertib and Zotatifin, are being evaluated in Phase 2 clinical trials for various solid tumors, including non-small cell lung cancer and breast cancer. The company is also exploring partnerships and collaborations to expand its pipeline and accelerate the development of its drug candidates. The goal is to improve patient outcomes by providing innovative cancer treatments with improved efficacy and reduced side effects. This segment's market positioning is based on its unique approach to cancer treatment, targeting translation regulation, and its competitive advantage lies in its innovative STRI platform. Future opportunities include expanding the clinical trials to include more cancer types and developing combination therapies with existing cancer treatments. Regulatory aspects include obtaining FDA approval for the drug candidates.